Loading...

ENDRA Life Sciences

Nasdaq:NDRA
Snowflake Description

Adequate balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NDRA
Nasdaq
$12M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

ENDRA Life Sciences Inc. develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. The last earnings update was 37 days ago. More info.


Add to Portfolio Compare Print
  • ENDRA Life Sciences has significant price volatility in the past 3 months.
NDRA Share Price and Events
7 Day Returns
-3.6%
NasdaqCM:NDRA
1.5%
US Medical Equipment
1.2%
US Market
1 Year Returns
-35.5%
NasdaqCM:NDRA
14.6%
US Medical Equipment
2.3%
US Market
NDRA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ENDRA Life Sciences (NDRA) -3.6% 35% -49.5% -35.5% - -
US Medical Equipment 1.5% 7.4% 2.7% 14.6% 63.8% 98.7%
US Market 1.2% 2% 2% 2.3% 37.9% 39.8%
1 Year Return vs Industry and Market
  • NDRA underperformed the Medical Equipment industry which returned 14.6% over the past year.
  • NDRA underperformed the Market in United States of America which returned 2.3% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is ENDRA Life Sciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for ENDRA Life Sciences. This is due to cash flow or dividend data being unavailable. The share price is $1.62.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ENDRA Life Sciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ENDRA Life Sciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:NDRA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-1.81
NasdaqCM:NDRA Share Price ** NasdaqCM (2019-06-19) in USD $1.62
United States of America Medical Equipment Industry PE Ratio Median Figure of 64 Publicly-Listed Medical Equipment Companies 41.06x
United States of America Market PE Ratio Median Figure of 3,092 Publicly-Listed Companies 17.87x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ENDRA Life Sciences.

NasdaqCM:NDRA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:NDRA Share Price ÷ EPS (both in USD)

= 1.62 ÷ -1.81

-0.9x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ENDRA Life Sciences is loss making, we can't compare its value to the US Medical Equipment industry average.
  • ENDRA Life Sciences is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does ENDRA Life Sciences's expected growth come at a high price?
Raw Data
NasdaqCM:NDRA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.9x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
-1%per year
United States of America Medical Equipment Industry PEG Ratio Median Figure of 55 Publicly-Listed Medical Equipment Companies 2.3x
United States of America Market PEG Ratio Median Figure of 2,128 Publicly-Listed Companies 1.53x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ENDRA Life Sciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ENDRA Life Sciences's assets?
Raw Data
NasdaqCM:NDRA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.51
NasdaqCM:NDRA Share Price * NasdaqCM (2019-06-19) in USD $1.62
United States of America Medical Equipment Industry PB Ratio Median Figure of 183 Publicly-Listed Medical Equipment Companies 4.44x
United States of America Market PB Ratio Median Figure of 5,246 Publicly-Listed Companies 1.8x
NasdaqCM:NDRA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:NDRA Share Price ÷ Book Value per Share (both in USD)

= 1.62 ÷ 0.51

3.16x

* Primary Listing of ENDRA Life Sciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ENDRA Life Sciences is good value based on assets compared to the US Medical Equipment industry average.
X
Value checks
We assess ENDRA Life Sciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. ENDRA Life Sciences has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is ENDRA Life Sciences expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ENDRA Life Sciences expected to grow at an attractive rate?
  • Unable to compare ENDRA Life Sciences's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare ENDRA Life Sciences's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • ENDRA Life Sciences's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:NDRA Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:NDRA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts -1%
NasdaqCM:NDRA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 105.8%
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 22%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.9%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:NDRA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:NDRA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 7 -8 -9 1
2020-12-31 2 -9 -12 3
2019-12-31 0 -9 -11 3
NasdaqCM:NDRA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 0 -8 -10
2018-12-31 0 -8 -10
2018-09-30 0 -7 -10
2018-06-30 0 -6 -8
2018-03-31 0 -6 -7
2017-12-31 0 -3 -5
2017-09-30 1 -2 -4
2017-06-30 1 -2 -4
2017-03-31 1 -1 -3
2016-12-31 1 -1 -3
2016-09-30 0 -1 -3
2016-06-30 1 -1 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • ENDRA Life Sciences is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • ENDRA Life Sciences's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:NDRA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from ENDRA Life Sciences Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:NDRA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -0.74 -0.74 -0.74 1.00
2020-12-31 -1.44 -0.99 -2.21 3.00
2019-12-31 -1.40 -1.29 -1.51 3.00
NasdaqCM:NDRA Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -1.81
2018-12-31 -2.17
2018-09-30 -2.48
2018-06-30 -2.01
2018-03-31 -2.10
2017-12-31 -1.95
2017-09-30 -1.93
2017-06-30 -3.33
2017-03-31 -4.34
2016-12-31 -3.84
2016-09-30 -3.52
2016-06-30 -3.15

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ENDRA Life Sciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess ENDRA Life Sciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ENDRA Life Sciences has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has ENDRA Life Sciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ENDRA Life Sciences's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ENDRA Life Sciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare ENDRA Life Sciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ENDRA Life Sciences's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
ENDRA Life Sciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ENDRA Life Sciences Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:NDRA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 0.00 -9.72 3.81 4.83
2018-12-31 0.01 -9.80 4.02 4.72
2018-09-30 0.01 -9.73 4.00 5.03
2018-06-30 0.30 -7.88 3.88 4.17
2018-03-31 0.36 -7.46 3.78 3.50
2017-12-31 0.35 -5.38 2.87 1.93
2017-09-30 0.86 -3.77 2.37 0.73
2017-06-30 0.57 -3.84 2.06 0.57
2017-03-31 0.52 -3.14 1.56 0.50
2016-12-31 0.52 -2.78 1.58 0.50
2016-09-30 0.26 -2.55 1.45 0.61
2016-06-30 0.58 -2.26 1.40 0.73
2016-03-31 1.00 -2.09 1.28 0.88
2015-12-31 1.41 -2.28 1.27 1.04
2014-12-31 0.56 -2.18 0.95 0.87

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ENDRA Life Sciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ENDRA Life Sciences has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ENDRA Life Sciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ENDRA Life Sciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ENDRA Life Sciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is ENDRA Life Sciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ENDRA Life Sciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ENDRA Life Sciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ENDRA Life Sciences has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ENDRA Life Sciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • ENDRA Life Sciences has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ENDRA Life Sciences Company Filings, last reported 2 months ago.

NasdaqCM:NDRA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 3.80 0.00 3.93
2018-12-31 6.25 0.02 6.47
2018-09-30 -0.46 0.73 0.64
2018-06-30 1.94 0.42 2.21
2018-03-31 2.83 0.00 3.15
2017-12-31 5.28 0.00 5.60
2017-09-30 7.17 0.00 6.98
2017-06-30 7.78 0.00 7.52
2017-03-31 -1.38 1.30 0.13
2016-12-31 -0.89 0.95 0.14
2016-09-30 -0.24 0.61 0.08
2016-06-30 0.27 0.27 0.50
2016-03-31 0.25 0.00 0.02
2015-12-31 0.25 0.00 0.02
2014-12-31 0.61 0.00 0.16
  • ENDRA Life Sciences has no debt.
  • ENDRA Life Sciences currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ENDRA Life Sciences has less than a year of cash runway based on current free cash flow.
  • ENDRA Life Sciences has less than a year of cash runway if free cash flow continues to grow at historical rates of 77% each year.
X
Financial health checks
We assess ENDRA Life Sciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ENDRA Life Sciences has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is ENDRA Life Sciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ENDRA Life Sciences dividends.
If you bought $2,000 of ENDRA Life Sciences shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ENDRA Life Sciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ENDRA Life Sciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:NDRA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2011 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:NDRA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ENDRA Life Sciences has not reported any payouts.
  • Unable to verify if ENDRA Life Sciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ENDRA Life Sciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ENDRA Life Sciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess ENDRA Life Sciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ENDRA Life Sciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ENDRA Life Sciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of ENDRA Life Sciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Francois Michelon
COMPENSATION $724,553
AGE 52
TENURE AS CEO 3.9 years
CEO Bio

Mr. Francois Michelon has been the Chairman and Chief Executive Officer of ENDRA Life Sciences Inc. since July 2015. Mr. Michelon joined ENDRA in 2015. He has 20 years of healthcare technology experience in general management, operations, strategy and marketing across the diagnostic imaging, surgical instrument and dental sectors. He has extensive industry and executive experience. From 2012 to 2014, Mr. Michelon served as Vice President of Global Marketing for Biomet Corporation’s 3i division, a provider of oral reconstruction technologies. He was responsible for the upstream and downstream development of 3i’s global portfolio. From 2004 to 2011, Mr. Michelon served as Group Director of Global Services and Visualization for Smith & Nephew’s Advanced Surgical Devices division, where he led P&L’s in the B2B service and capital equipment sectors. From 1997 to 2004, he worked at GE Healthcare in a variety of upstream and downstream marketing roles. He also earned his Six Sigma Black Belt certification. Mr. Michelon earned an MBA from Carnegie-Mellon University and a BA in Economics from The University of Chicago.

CEO Compensation
  • Francois's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Francois's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the ENDRA Life Sciences management team in years:

4.7
Average Tenure
51
Average Age
  • The tenure for the ENDRA Life Sciences management team is about average.
Management Team

Francois Michelon

TITLE
Chairman & CEO
COMPENSATION
$725K
AGE
52
TENURE
3.9 yrs

David Wells

TITLE
CFO & Secretary
COMPENSATION
$211K
AGE
56
TENURE
5.4 yrs

Michael Thornton

TITLE
Chief Technology Officer
COMPENSATION
$592K
AGE
50
TENURE
12.4 yrs

Jonathan Behr

TITLE
Co-Founder

Steve Freeman

TITLE
Human Resources Leader
TENURE
2.1 yrs

Renaud Maloberti

TITLE
Chief Commercial Officer
AGE
49
Board of Directors Tenure

Average tenure and age of the ENDRA Life Sciences board of directors in years:

5.2
Average Tenure
55
Average Age
  • The tenure for the ENDRA Life Sciences board of directors is about average.
Board of Directors

Alex Tokman

TITLE
Independent Director
COMPENSATION
$78K
AGE
56
TENURE
11.4 yrs

Francois Michelon

TITLE
Chairman & CEO
COMPENSATION
$725K
AGE
52
TENURE
3.9 yrs

Mike Harsh

TITLE
Independent Director
COMPENSATION
$78K
AGE
64
TENURE
3.9 yrs

Anthony DiGiandomenico

TITLE
Independent Director
COMPENSATION
$78K
AGE
51
TENURE
6.4 yrs

Sanjiv Gambhir

TITLE
Independent Director
COMPENSATION
$78K
AGE
55
TENURE
11.4 yrs

Jonathan Rubin

TITLE
Scientific Advisor
TENURE
3.8 yrs

Jing Gao

TITLE
Scientific Advisor
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by ENDRA Life Sciences insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
14. Jun 19 Buy Michael Harsh Individual 10. Jun 19 10. Jun 19 500 $1.14 $570
10. Jun 19 Buy Michael Harsh Individual 05. Jun 19 07. Jun 19 9,500 $1.20 $10,582
20. May 19 Buy Michael Thornton Individual 16. May 19 16. May 19 30,000 $1.13 $33,900
25. Oct 18 Sell Longboard Capital Advisors Company 22. Oct 18 24. Oct 18 -130,200 $4.22 $-545,246
X
Management checks
We assess ENDRA Life Sciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ENDRA Life Sciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Imagine Owning ENDRA Life Sciences (NASDAQ:NDRA) And Wondering If The 32% Share Price Slide Is Justified

Check out our latest analysis for ENDRA Life Sciences With zero revenue generated over twelve months, we don't think that ENDRA Life Sciences has proved its business plan yet. … It seems likely some shareholders believe that ENDRA Life Sciences will significantly advance the business plan before too long. … A Different Perspective While ENDRA Life Sciences shareholders are down 32% for the year, the market itself is up 3.1%.

Simply Wall St -

Can We See Significant Institutional Ownership On The ENDRA Life Sciences Inc. (NASDAQ:NDRA) Share Register?

A look at the shareholders of ENDRA Life Sciences Inc. … Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … ENDRA Life Sciences is not a large company by global standards.

Simply Wall St -

Can We See Significant Insider Ownership On The ENDRA Life Sciences Inc (NASDAQ:NDRA) Share Register?

A look at the shareholders of ENDRA Life Sciences Inc (NASDAQ:NDRA) can tell us which group is most powerful. … ENDRA Life Sciences is not a large company by global standards. … View our latest analysis for ENDRA Life Sciences

Simply Wall St -

Who Are ENDRA Life Sciences Inc's (NASDAQ:NDRA) Major Shareholders?

In this article, I'm going to take a look at ENDRA Life Sciences Inc’s (NASDAQ:NDRA) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … Check out our latest analysis for ENDRA Life Sciences

Simply Wall St -

When Will ENDRA Life Sciences Inc (NASDAQ:NDRA) Come Back To Market?

Today I’ve examined ENDRA Life Sciences’s financial data from its most recent earnings update, to roughly assess when the company may need to raise new capital. … NasdaqCM:NDRA Income Statement Jun 1st 18 When will ENDRA Life Sciences need to raise more cash? … My cash burn analysis suggests that, if ENDRA Life Sciences continues to spend its cash reserves at this current high rate, it’ll have to raise capital within the next 6 months, which may be a surprise to some shareholders.

Simply Wall St -

How Should Investors React To ENDRA Life Sciences Inc's (NASDAQ:NDRA) CEO Pay?

Performance can be measured based on factors such as earnings and total shareholder return (TSR). … Most recently, NDRA delivered negative earnings of -US$7.46M , which is a further decline from prior year's loss of -US$3.14M. … Usually I would use earnings and market cap to account for variations in performance, however, NDRA's negative earnings reduces the usefulness of my formula.

Simply Wall St -

With A -93.74% Earnings Drop, Is ENDRA Life Sciences Inc's (NASDAQ:NDRA) A Concern?

Investors with a long-term horizong may find it valuable to assess ENDRA Life Sciences Inc's (NASDAQ:NDRA) earnings trend over time and against its industry benchmark as opposed to simply looking at a sincle earnings announcement at one point in time. … NasdaqCM:NDRA Income Statement Apr 16th 18 We can further assess ENDRA Life Sciences's loss by looking at what the industry has been experiencing over the past few years. … Each year, for the past five years ENDRA Life Sciences has seen an annual decline in revenue of -18.39%, on average.

Simply Wall St -

What You Must Know About ENDRA Life Sciences Inc's (NASDAQ:NDRA) Major Investors

With hardly any institutional ownership, NDRA stock poses limited concern relating to the effect institutional block trades have on its stock price. … Private Company Ownership Another important group of owners for potential investors in NDRA are private companies that hold a stake of 1.46% in NDRA. … Thus, investors not need worry too much about the consequences of these holdings.Next Steps: Institutional ownership level and composition in NDRA is not high nor active enough to significantly impact its investment thesis.

Simply Wall St -

When Will ENDRA Life Sciences Inc (NASDAQ:NDRA) Run Out Of Money?

See our latest analysis for ENDRA Life Sciences What is cash burn? … NasdaqCM:NDRA Income Statement Feb 27th 18 When will ENDRA Life Sciences need to raise more cash? … According to my analysis, if ENDRA Life Sciences continues to grow at this rate, it will burn through its cash reserves by the next 2.1 years, and may be coming to market again.

Simply Wall St -

Does ENDRA Life Sciences Inc's (NASDAQ:NDRA) CEO Pay Reflect Performance?

Performance can be measured based on factors such as earnings and total shareholder return (TSR). … In the past year, NDRA delivered negative earnings of -$3.8M , which is a further decline from prior year's loss of -$2.5M. … Typically I'd use market cap and profit as factors determining performance, however, NDRA's negative earnings reduces the effectiveness of this method.

Simply Wall St -

Company Info

Description

ENDRA Life Sciences Inc. develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person’s body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. It also offers Nexus-128 system that combines light-based thermos-acoustics and ultrasound to address the imaging needs of researchers studying disease models in pre-clinical applications. ENDRA Life Sciences Inc. has collaborative research agreement with General Electric Company. The company was incorporated in 2007 and is based in Ann Arbor, Michigan.

Details
Name: ENDRA Life Sciences Inc.
NDRA
Exchange: NasdaqCM
Founded: 2007
$12,024,680
7,422,642
Website: http://www.endrainc.com
Address: ENDRA Life Sciences Inc.
3600 Green Court,
Suite 350,
Ann Arbor,
Michigan, 48105,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM NDRA Common Stock Nasdaq Capital Market US USD 29. Jun 2017
Number of employees
Current staff
Staff numbers
11
ENDRA Life Sciences employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/20 00:50
End of day share price update: 2019/06/19 00:00
Last estimates confirmation: 2019/06/13
Last earnings filing: 2019/05/14
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.